Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, a seasoned capital markets expert with approximately 20 years of experience, will oversee communications with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who has led the department and played a pivotal role in building Medios' investor relations activities.
Neuffer brings a wealth of experience to the role, having previously served as Head of Investor Relations & Corporate Communications at SDAX-listed Wacker Neuson SE from 2007 to 2018, where she guided the company from its IPO to becoming a consistently attractive investment. She also led the Strategy and Sustainability departments there. Later, as Vice President Investor Relations & Corporate Communications and Marketing at Exyte Group (formerly M+W Group), she managed an international team of 20 and was responsible for preparing an IPO with a targeted market capitalization of over EUR 2 billion. Since 2020, she has worked as an independent consultant, advising publicly listed companies on investor relations, IPO preparation, and crisis and restructuring communications.
The appointment comes at a crucial time for Medios, as the company seeks to reposition itself in the capital markets and intensify its dialogue with investors, analysts, and the media. Thomas Meier, CEO of Medios AG, expressed confidence in Neuffer's abilities, stating, "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media."
Meier also thanked Claudia Nickolaus for her contributions, saying, "On behalf of the Company, I would like to express my sincere thanks to Claudia Nickolaus: Over many years, she shaped Medios' capital markets communications with tremendous dedication, a high level of professionalism, and personal reliability. She deserves our sincere gratitude for this."
Medios, as Germany's first listed specialty pharmaceutical company, is focused on pioneering individualized medicine to make innovative therapies accessible. The company operates across Germany, the Netherlands, Belgium, and Spain, providing innovative solutions and intelligent services to key partners in the supply chain. Its shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.
Looking ahead, Medios has several important events scheduled for the 2026 financial year, including the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day on September 28 and 29, and the Quarterly Statement as of September 30 on November 10. These events will be key opportunities for Neuffer to engage with the financial community and further Medios' strategic objectives.
For more information about Medios and its initiatives, visit their website at www.medios.group and learn more about individualized medicine at app.medios.group/en/individualizedmedicine.
